How do you see the latest launch of the diabetic drug by Glenmark?

Glenmark Pharma has just launched a fixed-dose combination drug for the treatment of Type 2 diabetes in India. This is an affliction that has been rising in India sharply with the change in food habits, limited exercise and largely sedentary lifestyles. Glenmark has been a key player in the anti-diabetic drugs segment in India.

The drug is a combination of Remogliflozin Etabonate and Vildagliptin for management of Type 2 diabetes. In terms of key chemical components, the diabetes drug of Glenmark has Remogliflozin (100 mg) and Vildagliptin (50 mg) to be taken twice in a day to improve glycemic control in patients. It is unregulated glucose that leads to diabetes.

Glenmark has launched these products under two distinct brands viz. Remo V and Remozen V. Glenmark had secured approval for the drug from the Indian Pharma Regulator, DCGI, in late November 2020. Glenmark drug is also substantially economical in price terms. Glenmark's Remogliflozin-Vildagiptin combination is available at Rs.14 per tablet as compared to Rs.78 for other drugs.

This has been instrumental in reducing the cost of treatment substantially. There are 7.7 crore adults in India with diabetes as of end-2019 and it is almost like a health crisis in India if not addressed quickly at an economical cost.